Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
New Approaches to Neuroblastoma Therapy Consortium
With
National Cancer Institute (NCI)
Age
2–30
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients must be \> 2 years and \< 30 years of age when registered on study.
Patients must have recurrent/progressive high-risk neuroblastoma, refractory high-risk neuroblastoma that had less than a partial response to standard treatment or persistent high-risk neuroblastoma that had at least a partial response to standard treatment.
All patients must have at least ONE site of evaluable disease.
Patients must have adequate heart, kidney, liver and bone marrow function.
Patients who have bone marrow disease must still have adequate bone marrow function to enter the study.
Patients with other ongoing serious medical issues must be approved by the study chair prior to registration.
Patients with active bleeding of the GI tract or patients who have symptoms associated with stomach irritation (known as gastritis).
Patients who have had a seizure within 12 months prior to enrollment and patients receiving anti-convulsant therapy for a seizure disorder.
Patients with known Aspirin-Hypersensitivity triad (asthma, allergic rhinitis, ASA hypersensitivity).
Patients with known hypersensitivity to celecoxib or other NSAIDs, aspirin or sulfonamides.
You may not be if
Females of childbearing potential that do not have a negative pregnancy test.
Patients that are pregnant, breast feeding, or unwilling to use effective contraception during the study
Patients status post allogeneic stem cell transplant.
Patients who, in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study.
Patients with disease of any major organ system that would compromise their ability to withstand therapy.
Patients who are on hemodialysis.
Clareo Health | N2012-01: Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/Topotecan
